Name | Thailanstatin D |
---|
Description | Thailanstatin D, an analogue of Thailanstatin A, is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3' splice site. Thailanstatin D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis[1]. |
---|---|
Related Catalog | |
In Vitro | Thailanstatin D (0-50 nM; 4 hours) significantly decreases the protein levels of AR-V7 and other AR-Vs (AR splice variants)[1]. Cell Viability Assay[1] Cell Line: VCaP, 22RV1 and LN95 cells Concentration: 0-50 nM Incubation Time: 4 hours Result: The mRNA levels of both AR-V7 and AR-FL were suppressed by Thailanstatin D in a dose-dependent manner. |
In Vivo | Thailanstatin D (300 µg/kg; ALZET osmotic pumps; daily for 4 days) significantly inhibits the tumor growth[1]. Animal Model: NOD-SCID mice ( Mice bearing 22RV1 xenografts)[1] Dosage: 300 µg/kg Administration: ALZET osmotic pumps; daily for 4 days Result: Significantly inhibited the tumor growth. |
References |
Molecular Formula | C28H41NO8 |
---|---|
Molecular Weight | 519.63 |